--- title: "Quoin Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285612515.md" datetime: "2026-05-07T20:28:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285612515.md) - [en](https://longbridge.com/en/news/285612515.md) - [zh-HK](https://longbridge.com/zh-HK/news/285612515.md) --- # Quoin Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -1.77, beating the estimate of USD -2.0167. EBIT: As of FY2026 Q1, the actual value is USD -5.278 M. ### Financial Highlights #### Cash and Investments Quoin Pharmaceuticals, Ltd. had approximately $14 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Cash and cash equivalents were $3,124,522 as of March 31, 2026, compared to $3,818,096 as of December 31, 2025. Investments were $10,918,778 as of March 31, 2026, compared to $14,927,165 as of December 31, 2025. #### Net Loss Net loss for the quarter ended March 31, 2026, was approximately - $5 million, compared to approximately - $3.8 million for the quarter ended March 31, 2025. The specific net loss was - $4,997,736 for the three months ended March 31, 2026, compared to - $3,812,179 for the three months ended March 31, 2025. #### Operating Expenses - General and administrative expenses were $1,697,448 for the three months ended March 31, 2026, up from $1,583,038 for the same period in 2025. - Research and development expenses were $3,433,763 for the three months ended March 31, 2026, up from $2,374,139 for the same period in 2025. - Total operating expenses were $5,131,211 for the three months ended March 31, 2026, compared to $3,957,177 for the three months ended March 31, 2025. #### Other Income/Loss - Unrealized gain (loss) was $13,300 for the three months ended March 31, 2026, compared to - $126 for the same period in 2025. - Realized and accrued interest income was - $146,775 for the three months ended March 31, 2026, compared to - $144,872 for the same period in 2025. - Total other income was - $133,475 for the three months ended March 31, 2026, compared to - $144,998 for the three months ended March 31, 2025. #### Comprehensive Loss - Comprehensive loss was - $4,997,282 for the three months ended March 31, 2026, compared to - $3,812,179 for the three months ended March 31, 2025. #### Balance Sheet Items (as of March 31, 2026 vs. December 31, 2025) - Total current assets were $15,334,556 compared to $20,007,235. - Total assets were $15,692,890 compared to $20,390,569. - Total current liabilities were $5,346,026 compared to $5,546,930. - Total liabilities were $6,919,759 compared to $7,270,663. - Total shareholders’ equity was $8,773,131 compared to $13,119,906. ### Operational Metrics (Regulatory & Clinical Progress) Quoin Pharmaceuticals, Ltd. filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority (SFDA) for QRX003 on January 20, 2026. On January 27, 2026, the company submitted an application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Orphan Drug Designation for QRX003, which MHLW confirmed qualified for both ODD and Fast Track review. The U.S. FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome on March 11, 2026. A Type C meeting with the FDA indicated that a single Phase 3 study might suffice for U.S. marketing approval for QRX003, with openness to alternative study designs. The U.S. Rare Pediatric Disease Priority Review Voucher (PRV) program was extended by Congress through September 30, 2029. Clinical evaluation of QRX003 lotion (4%) in late-stage whole-body clinical trials for Netherton Syndrome continues, with topline data anticipated in the second half of 2026. The pediatric investigator-led study for QRX003 has been expanded to six children, and the Peeling Skin Syndrome (PSS) program’s investigator-led study for QRX003 has also expanded to six subjects. The company is advancing its QRX009 topical rapamycin platforms, planning investigator-led clinical studies for various indications, including Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. ### Outlook / Guidance Quoin Pharmaceuticals, Ltd. expects to complete Phase 3 patient recruitment for QRX003 by the end of 2026, with a potential New Drug Application (NDA) filing in 2027. The company also plans to submit an Investigational New Drug (IND) Application to the FDA for QRX009 for an additional indication by Q3 2026. Quoin Pharmaceuticals, Ltd. believes its current cash position of approximately $14 million will fund operations into 2027. ### Related Stocks - [QNRX.US](https://longbridge.com/en/quote/QNRX.US.md) ## Related News & Research - [Quoin Pharmaceuticals Provides Clinical And Regulatory Update From Constructive Type C Meeting With U.S. FDA For Qrx003 In Netherton Syndrome](https://longbridge.com/en/news/280472878.md) - [Quoin Updates On Type C Meet With FDA For QRX003 In NS; On Track To Initiate Phase 3 Trial In 2026](https://longbridge.com/en/news/280577647.md) - [Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays](https://longbridge.com/en/news/280868121.md) - [Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group](https://longbridge.com/en/news/285751595.md) - [Quoin Pharmaceuticals 10-K: Net loss $15.8M, Cash $18.7M, EPS pressure](https://longbridge.com/en/news/280686598.md)